Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
231 patients around the world
Available in Argentina, United States
Immunovant Sciences GmbH
231Patients around the world
This study is for people with
Myasthenia gravis
Generalized myasthenia gravis
Requirements for the patient
To 80 Years
All Gender
Medical requirements
Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit.
Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1).
Additional inclusion criteria are defined in the protocol.
Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit.
Have had a thymectomy performed < 6 months prior to the Screening Visit or have a planned thymectomy during the study.
Have any active or untreated malignant thymoma.
Additional exclusion criteria are defined in the protocol.
